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Abstract
Background: Medical advancements have resulted in better survival and life expec‐
tancy among those with spina bifida, but a significantly increased risk of perinatal and 
postnatal mortality for individuals with spina bifida remains.
Objectives: To examine stillbirth and infant and child mortality among those affected 
by spina bifida using data from multiple countries.
Methods: We conducted an observational study, using data from 24 population‐ and 
hospital‐based surveillance registries in 18 countries contributing as members of the 
International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). 
Cases of spina bifida that resulted in livebirths or stillbirths from 20 weeks' gesta‐
tion or elective termination of pregnancy for fetal anomaly (ETOPFA) were included. 
Among liveborn spina bifida cases, we calculated mortality at different ages as num‐
ber of deaths among liveborn cases divided by total number of liveborn cases with 
spina bifida. As a secondary outcome measure, we estimated the prevalence of spina 
bifida per 10 000 total births. The 95% confidence interval for the prevalence esti‐
mate was estimated using the Poisson approximation of binomial distribution.
Results: Between years 2001 and 2012, the overall first‐week mortality proportion 
was 6.9% (95% CI 6.3, 7.7) and was lower in programmes operating in countries with 
policies that allowed ETOPFA compared with their counterparts (5.9% vs. 8.4%). The 
majority of first‐week mortality occurred on the first day of life. In programmes where 
information on long‐term mortality was available through linkage to administrative 
databases, survival at 5 years of age was 90%‐96% in Europe, and 86%‐96% in North 
America.
Conclusions: Our multi‐country study showed a high proportion of stillbirth and in‐
fant and child deaths among those with spina bifida. Effective folic acid interventions 
could prevent many cases of spina bifida, thereby preventing associated childhood 
morbidity and mortality.
K E Y W O R D S
epidemiology, mortality, registry‐based study, spina bifida
1  | BACKGROUND
Spina bifida is a common and major congenital disorder of the central 
nervous system characterised by incomplete or incorrect closure of the 
neural tube during the embryonic development.1 Spina bifida affects 
over 150 000 births worldwide and contributes to significant disability 
and child mortality.2 The observed prevalence of spina bifida varies 
globally and is largely influenced by differences in surveillance meth‐
ods, prenatal diagnosis and elective termination policies, and folic acid 
fortification of staple foods in a given country or region.3‐5 Evidence 
from both randomised clinical trials and observational studies shows 
that many cases of spina bifida can be prevented by women taking 
400‐800 mcg/day of folic acid during preconception and early preg‐
nancy.6‐9 The United States Preventive Services Task Force (USPSTF) 
recommends that all women planning or capable of pregnancy take a 
daily supplement containing 0.4‐0.8 mg (400‐800 mcg) of folic acid.10
Medical advancements since the 1960s, especially in developed 
countries, have resulted in better survival and life expectancy among 
those with spina bifida.11 But even with improved medical care, 
studies show a significantly increased risk of perinatal and postnatal 
mortality for individuals with spina bifida compared to those with‐
out.1,12‐18 Mortality associated with spina bifida is more frequent in 
countries with fewer resources and less health care access compared 
with their counterparts in high‐income regions of the world.1,2,4,5 Few 
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studies have been conducted that examined mortality associated 
with spina bifida, and most of them were conducted in developed 
countries.15,16,19,20 Wang et al conducted a population‐based analysis 
examining the survival of children with spina bifida in New York State 
in the United States. In this large population‐based study examining 
children born with spina bifida between years 1983 and 2006, the 
probability of survival was 93% up to age 7 days, 92% up to 1 month, 
88% up to 1 year, 86% up to 5 years, and 82% up to 25 years.16 Time 
trends in spina bifida survival are also not well examined globally; 
two studies from the United States and Canada showed an improve‐
ment in survival among cohorts born in later years compared with 
those born during the late 1970s and the early 1980s.17,20,21
There are opportunities to study mortality among infants born 
with spina bifida utilising pooled data from large networks of estab‐
lished birth defects surveillance systems, which have a potential to 
link to death certificates or other administrative health data sets. 
The primary objective of our study was to examine perinatal and in‐
fant and child mortality for those affected by spina bifida using data 
from multiple birth defects registries affiliated with the International 
Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) 
and examine temporal trends in mortality. As a secondary objective, 
we examined the total prevalence of spina bifida using data from 
participating programmes. We were also able to stratify by the avail‐
ability of elective termination for fetal anomalies (ETOPFA) on peri‐
natal and infant and child mortality.
2  | METHODS
2.1 | Study design and setting
International Clearinghouse for Birth Defects Surveillance and 
Research was established in 1974 and is a voluntary non‐profit or‐
ganisation affiliated with the World Health Organization (http://
www.icbdsr.org/). As a consortium of birth defects surveillance and 
research programmes from around the world, ICBDSR investigates 
and aims to prevent birth defects and minimise any negative con‐
sequences associated with them. As of 2018, there are 42 birth de‐
fects surveillance programmes in ICBDSR, either population‐based 
or hospital‐based, of which 27 contribute data on an annual basis. 
These registries provide aggregated data on children and fetuses 
affected with at least one of 39 different birth defects to ICBDSR 
for surveillance purposes (a list of all monitoring programmes and 
their surveillance attributes can be found at http://www.icbdsr.org/
wp‐conte nt/annual_repor t/Repor t2014.pdf). Each programme also 
collects data on the total annual number of livebirths and stillbirths 
in their source population for each of the surveillance years to aid in 
prevalence estimation.
For the current analysis, each programme contributed data for 
the longest period available, and in general, this period included the 
year the surveillance programme started until year 2015 or last year 
of the surveillance (Figure 1). We used data from 24 ICBDSR member 
registries or programmes, representing 18 countries in Asia, Europe, 
North America, and South America. Programmes were eligible to 
participate in the study if they collected data on both spina bifida 
prevalence and mortality among infants born with spina bifida. For 
each programme in our study, we examined indicators describing the 
type of registry (population‐based vs. hospital‐based systems), cov‐
erage, ascertainment period, stillbirth definition, ETOPFA allowed 
and availability of prenatal screening services (Table 1). Each pro‐
gramme has local procedures for ethics approval, and because this 
study was done using aggregated data, no additional ethics commit‐
tee approval was required.
2.2 | Spina bifida—Case definition
International Clearinghouse for Birth Defects Surveillance and 
Research defined spina bifida as ‘a family of congenital malformation 
defects in the closure of the spinal column characterized by hernia‐
tion or exposure of the spinal cord and/or meninges through an in‐
completely closed spine. Includes: meningocele, meningomyelocele, 
myelocele, myelomeningocele, and rachischisis. Spina bifida is not 
counted when present with anencephaly. Excludes: spina bifida oc‐
culta, sacrococcygeal teratoma without dysraphism’. This case defi‐
nition corresponds to International Classification of Disease (ICD)‐10 
code ‘Q05’ and ICD‐9 code ‘741’. Individual ICBDSR programmes 
provided information on the annual number of cases with spina bi‐
fida and the pregnancy outcome (livebirth, stillbirth, ETOPFA). Spina 
bifida cases were further classified based on clinical presentation 
(isolated, multiple congenital anomalies [MCA], syndromic). Isolated 
cases were defined as those with spina bifida, but with no other 
Synopsis
Study question
To examine perinatal and infant and child mortality and its 
trends for those affected with spina bifida.
What is already known
Medical advancements have resulted in better survival and 
life expectancy among those with spina bifida, but a sig‐
nificantly increased risk of perinatal and infant and child 
mortality remains.
What this study adds
Our multi‐country study showed perinatal and infant and 
child mortality is a major concern for those with spina bi‐
fida. The overall first‐week mortality proportion was lower 
in programmes with policies that allowed elective termi‐
nations of pregnancy for fetal anomalies compared with 
those that did not. The proportion of perinatal and infant 
and child deaths were higher among spina bifida cases with 
co‐occurring unrelated major anomalies or genetic syn‐
dromes compared with those with isolated spina bifida.
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co‐occurring unrelated major birth defects. The definition of MCA 
included spina bifida co‐occurring with one or more unrelated major 
anomalies. A case was defined as ‘syndromic’ when the spina bifida 
was part of a genetic disorder or a recognised syndrome.
2.3 | Mortality
Information on mortality was based on several follow‐up methods 
as applied by the surveillance programmes, including follow‐up until 
discharge from the hospital after birth, active or passive follow‐up of 
the children by clinicians or registry staff, or follow‐up by linking to 
administrative databases such as death records or other health care 
databases. Programmes could use more than one follow‐up method. 
In Table 2, we present the method of follow‐up that was applied in 
each programme. In our analysis, we examined mortality at different 
ages, including up to the first day of life, day 2‐6 (early neonatal), day 
7‐27 (late neonatal), day 28‐1 year (infant), 1‐4 years (under five), and 
≥5 years of age.
2.4 | Statistical analysis
We report results primarily per individual programme, and not as a 
pooled analysis, because some programmes contributed consider‐
ably more cases than others, and because our main goal was to 
examine variations across individual programmes and countries. 
For each programme, we calculated total prevalence of spina bi‐
fida as the total number of cases with spina bifida (livebirths + still‐
births +ETOPFA for spina bifida) divided by the total number of 
births (livebirths + stillbirths) in a specified time period. We esti‐
mated prevalence and 95% confidence interval for the prevalence 
estimate using the Poisson approximation of binomial distribution. 
We did not include ETOPFA in the denominator of the prevalence 
formula because of lack of data on the total number of termina‐
tions for each programme. We estimated the proportion of spina 
bifida‐affected pregnancies resulting in livebirths, stillbirths, and 
ETOPFA.
Among liveborn spina bifida cases, we calculated age‐specific 
mortality as number of deaths among liveborn cases divided by total 
number of liveborn cases with spina bifida, at different ages (day of 
birth, days 2‐6, days 7‐27, days 28‐1 year, 1‐4 years, and 5 years or 
greater), depending on programmes' availability (Table 2). We ex‐
amined long‐term mortality outcomes in a subset of programmes 
where linkages to death registration systems (death certificates) or 
other administrative databases allowed a lengthy follow‐up beyond 
the neonatal period. Survival proportion was calculated in each 
programme by extracting the cumulative proportion of cases who 
died at ages specified above from the total number of livebirths with 
spina bifida (set at 100% at birth). For programmes where data were 
F I G U R E  1   Spina bifida surveillance period by country and registry, International Clearinghouse for Birth Defects Surveillance and 
Research. 1Spain included information on elective termination of pregnancy for fetal anomalies from 1995 to 2014. 2Sweden included 
information on elective terminations of pregnancy for fetal anomalies from 1999 to 2014. 3Number of surveillance years. ECEMC, Registry 
of the Spanish Collaborative Study of Congenital Malformations; ECLAMC, Latin American Collaborative Study of Congenital Malformations; 
MCAR, Malta Congenital Anomalies Registry; OMNI‐Net = Ukraine Birth Defects Prevention Program; RENAC, National Network of 
Congenital Anomalies of Argentina; RYVEMCE, Mexican Registry and Epidemiological Surveillance of External Congenital Malformations; 
TROCA, Tabriz Registry of Congenital Anomalies; SMC, Soroka Medical Center; UK, United Kingdom; USA, United States of America
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TA B L E  1   Description of birth defects registries included in the spina bifida mortality study from registries contributing to the 










Argentina‐RENAC H N Hospital 
discharge
>500 g No Yes, but no official 
programme
Colombia‐Bogotá H R 1st day >500 g Yes, since 
2006
Yes
Colombia‐Cali H R 1st day >500 g Yes, since 
2006
Yes
South America‐ECLAMC H Ra Hospital 
discharge
>500 g Noe Yes
Czech Republic P N 15 y 22 wks or >500 g Yes Yes
France‐Paris P R 28 d 22 wks Yes Yes
Germany‐Saxony Anhalt P R 1 y >500 g Yes Yes, since 1990
Italy‐Lombardy P R 6 y 23 wks Yes Yes
Italy‐Tuscany P R 1 y 20 wks Yes yes
Malta‐MCAR P N 1 y 22 wks No Yes, gradually 
introduced
Netherlands‐Northern P R 10 y 24 wks Yes Yes, since 2007
Slovak Republic P N Hospital 
discharge
>500 g Yes Yes
Spain‐ECEMC H Rb 3 d 24 wks or 500 gd Yes, since 
1985
Yes
Sweden P N Before 1987 
1 mo,
After 1987 1 y
until 2006:28 wks,




Yes, since the early 
1980s
UK‐Wales P R 18 y 24 wks Yes Yes, since 2003
Ukraine‐OMNI‐Net P R 1 y until 2006:28 wks/>1000 g
2006 and after: 22 wks/>500 g
Yes Yes
Mexico‐Nuevo León P R 6 d Not included No Yes, only US
Mexico‐RYVEMCE H R 3 d >=20 gestational weeks or
>=500 g
No No
USA‐Arkansas P S 2 y 20 wks Yes, until 
20 wks
Yes
USA‐Atlanta P R 6 y 20 wks Yes Yes
USA‐Texas P S 1 y 20 wks Yes Yes
USA‐Utah P S 2 y 20 wks Yes Yes




Israel‐SMC H Rc Hospital 
discharge
Not included Yes, but not 
registered
Yes
Note: Column‐type of programme: H = hospital‐based, P = population‐based; column‐coverage: N = national, R = regional, S = statewide.
Abbreviations: ECEMC, Registry of the Spanish Collaborative Study of Congenital Malformations; ECLAMC, Latin American Collaborative Study of 
Congenital Malformations; ETOPFA, Elective Termination of Pregnancy for Fetal Anomalies; MCAR, Malta Congenital Anomalies Registry; OMNI‐
Net, Ukraine Birth Defects Prevention Program; RENAC, National Network of Congenital Anomalies of Argentina; RYVEMCE, Mexican Registry and 
Epidemiological Surveillance of External Congenital Malformations; SMC, Soroka Medical Center; TROCA, Tabriz Registry of Congenital Anomalies; 
UK, United Kingdom; USA, United States of America.
aSeveral regions in South America. 
bSeveral regions in Spain currently covering around 18% of total births. 
cReferral area of one hospital. 
dColumn‐stillbirth definition: if gestational age of death is not determined (since 1980). 
eColumn‐ETOPFA allowed except for anencephaly. 
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available, we examined mortality by isolated and non‐isolated case 
status (combining MCA and syndromic cases).
Finally, we examined trends in ETOPFA, stillbirth, and first‐week 
mortality for each programme for the total available study period. 
Because of small numbers, we calculated the proportion of spina 
bifida‐affected pregnancies resulting in ETOPFA, stillbirth, and 
first‐week mortality in livebirths by pooling 5‐year periods, starting 
from 1976 (or first year available) to 2014 (or last year available). We 
used 5‐year periods (1976‐1980, 1981‐1985, and so on); for some 
programmes, the first and last period may be fewer than 5 years. 
We did not report results by single years or for programmes that had 
fewer than 5 cases.
TA B L E  2   Description of follow‐up method for livebirths by registry from registries contributing to the International Clearinghouse for 
Birth Defects Surveillance and Research
Country‐registry
Follow‐up until discharge from 
the maternity hospital
Follow‐up by a clinician 
or registry staff
Linkage with death 
certificates
Maximum follow‐up period 
reported in study
Argentina‐RENAC Yes Yes No 1‐6 d
Colombia‐Bogotá Yes Yes No 1 d
Colombia‐Cali Yes Yes No No mortality reported for live 
births
South America‐ECLAMC Yes Yes No 28 d‐11 mo
Czech Republic No No Yes ≥5 y
France‐Paris Yes Yes No 7‐27 d
Germany‐Saxony Anhalt Yes Yesb No 1‐4 y
Italy‐Lombardy No No Yes, 2003 up to 
2015
1‐4 y
Italy‐Tuscany No No Yes, 1992 up to 
2015
28 d‐11 mo
Malta‐MCAR Yesa Yes Yesd 1‐4 y
Netherlands‐Northern Yes Yes No ≥5 y
Slovak Republic Yes No No 1‐6 d
Spain‐ECEMC Yes No No 1‐6 d
Sweden No No Yes, 1974 up to 
April 2016
≥5 y
UK‐Wales Yes No Yes, to GP system, 
till 18 y
≥5 y
Ukraine‐OMNI‐Net Yes Yes No 1‐4 y
Mexico‐Nuevo León Yes No No 1‐6 d
Mexico‐RYVEMCE Yes No No 1‐6 d
USA‐Arkansas Yes No Yes, 1993 up to 
2015
≥5 y
USA‐Atlanta Yes No Yes, 1979 up to 
2008
≥5 y
USA‐Texas Yes No Yes, 1996 up to 
2013
≥5 y
USA‐Utah Yes No Yes, until age 2 y ≥5 y
Iran‐TROCA Yes Yesc No 1‐6 d
Israel‐SMC Yes No Yes, 2000 up to 
2014
1‐4 y
Abbreviations: ECEMC, Registry of the Spanish Collaborative Study of Congenital Malformations; ECLAMC, Latin American Collaborative Study of 
Congenital Malformations; GP, General Practitioner; MCAR, Malta Congenital Anomalies Registry; OMNI‐Net, Ukraine Birth Defects Prevention 
Program; RENAC, National Network of Congenital Anomalies of Argentina; RYVEMCE, Mexican Registry and Epidemiological Surveillance 
of External Congenital Malformations; SMC, Soroka Medical Center; TROCA, Tabriz Registry of Congenital Anomalies; UK, United Kingdom; 
USA = United States of America.
Follow‐up method for livebirths:
aBabies are followed up until discharge, and their hospital files are again seen at 1 y of age, linkage with mortality data continues indefinitely. 
bUntil 18 years. 
cChildren in university hospital(s). 
dContinuous linkage with mortality register, for this study, data have linkage up to 2015. 
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3  | RESULTS
3.1 | Programme characteristics
A total of 24 ICBDSR member programmes with birth defects regis‐
tries representing 18 countries contributed data for a part or entire 
time period between years 1974 and 2015 examined in our analy‐
sis (Figure 1). Sixteen of the 24 registries were population‐based, 
with regional (n = 10), statewide (n = 3), or national (n = 3) coverage. 
The maximum age of ascertainment for birth defects varied by pro‐
gramme; however, most cases of spina bifida can be easily identified 
at birth. Criteria to define stillbirths also varied. ETOPFA was not 
TA B L E  3   Total number of births, total number of spina bifida cases and prevalence per 10 000 births, proportion of livebirth among 
total cases of spina bifida, proportion of stillbirths among total cases of spina bifida, and proportion of ETOPFA among total cases of spina 






















Argentina‐RENACa H 2009‐2012 422 173 241 5.7 (5.0, 6.5) 94.6 (91.0, 96.8) 5.0 (2.9, 8.5) –
Colombia‐Bogotáb H 2001‐2012 356 454 113 3.2 (2.6, 3.8) 92.0 (85.6, 95.6) 8.0 (4.2, 14.4) –
Colombia‐Calib H 2011‐2012 12 762 3 2.4 (0.5, 6.9) 100 (43.9, 100) 0 (0, 56.2) –
South 
America‐ECLAMCa
H 2001‐2012 1 847 181 1819 9.9 (9.4, 10.3) 93.5 (92.2, 
94.5)
6.5 (5.5, 7.8) –
Czech Republic P 2001‐2012 1 273 386 367 2.9 (2.6, 3.2) 37.9 (33.1, 42.9) 1.4 (0.6, 3.2) 60.8 (55.7,65.6)
France‐Paris P 2001‐2012 319 636 184 5.8 (5.0, 6.7) 18.5 (13.2, 24.7) 0.5 (0.1, 3.0) 81.0 (74.7, 86.0)
Germany‐Saxony 
Anhalt
P 2001‐2012 208 108 121 5.8 (4.8, 7.0) 33.8 (26.1, 42.7) 1.7 (0.5, 5.8) 64.5 (55.6, 72.4)
Italy‐Lombardy P 2003‐2012 133 182 64 4.8 (3.7, 6.1) 39.1 (28.1, 51.3) 1.6 (0.3, 8.3) 59.4 (47.2, 70.5)
Italy‐Tuscany P 2001‐2012 352 844 108 3.1 (2.5, 3.7) 20.4 (13.9, 28.9) 2.8 (1.0, 7.9) 76.5 (68.1, 83.8)
Malta‐MCARa P 2001‐2012 48 202 31 6.4 (4.4, 9.1) 90.3 (75.1, 96.7) 9.7 (3.3, 24.9) –
Netherlands‐Northern P 2001‐2012 221 846 106 4.8 (3.9, 5.8) 53.8 (44.3, 
63.0)
7.5 (3.9, 14.2) 38.7 (30.0, 48.2)
Slovak Republic P 2001‐2012 667 992 224 3.4 (2.9, 3.8) 79.9 (74.2, 84.6) 2.2 (1.0, 5.1) 17.9 (13.4, 23.4)
Spain‐ECEMC H 2001‐2012 259 285 156 6.0 (5.1, 7.0) 14.7 (10.0, 21.2) 0.6 (0.1, 3.5) 84.6 (78.1, 89.4)
Sweden P 2001‐2012 1 230 002 583 4.7 (4.4, 5.1) 45.1 (41.1, 49.2) 0.3 (0.1, 1.2) 54.5 (50.5, 58.5)
Ukraine‐OMNI‐Net P 2001‐2012 347 418 378 10.9 (9.8, 12.0) 44.7 (39.8, 49.8) 3.2 (1.8, 5.5) 47.4 (42.4, 52.4)
UK‐Wales P 2001‐2012 404 385 297 7.3 (6.5, 8.2) 26.3 (21.6, 31.6) 1.0 (0.3, 2.9) 72.7 (67.4, 77.5)
Mexico‐Nuevo Leóna P 2011‐2012 168 661 23 1.4 (0.9, 2.1) 100 (85.7, 100) 0 (0, 14.3) –
Mexico‐RYVEMCEa H 2001‐2012 264 306 169 6.4 (5.5, 7.4) 94.7 (90.2, 97.2) 5.3 (2.8, 9.8) –
USA‐Arkansas P 2001‐2012 470 593 207 4.4 (3.8, 5.0) 85.5 (80.1, 89.7) 4.8 (2.6, 8.7) 7.2 (4.4, 11.6)
USA‐Atlanta P 2001‐2008 428 976 180 4.2 (3.6, 4.9) 62.2 (55.0, 69.0) 8.9 (5.5, 14.0) 25.0 (19.2, 31.8)
USA‐Texas P 2001‐2012 4 668 071 1737 3.7 (3.6, 3.9) 90.8 (86.4, 92.1) 4.0 (3.2, 5.1) 5.1 (4.2, 6.3)
USA‐Utah P 2001‐2012 624 990 249 4.0 (3.5, 4.5) 85.5 (80.6, 89.4) 4.4 (2.5, 7.7) 10.0 (6.9, 14.4)
Iran‐TROCA H 2004‐2012 160 755 25 1.6 (1.0, 2.3) 88.0 (70.0, 
95.8)
4.0 (0.7, 19.5) 8 (2.2, 24.9)
Israel‐SMCc H 2001‐2012 158 544 47 3.0 (2.2, 3.9) 100 (92.4, 100) 0 (0, 7.6) –
Total  2001‐2012 15 049 752 7432 4.7 (4.6, 4.8) 73.2 (72.2, 
74.3)
4.1 (3.7, 4.6) 33.6 (32.0, 35.2)d
Abbreviations: CI, confidence Interval; ECEMC, Registry of the Spanish Collaborative Study of Congenital Malformations; ECLAMC, Latin American 
Collaborative Study of Congenital Malformations; ETOPFA, Elective Termination of Pregnancy for Fetal Anomalies; H, hospital‐based programme; 
MCAR, Malta Congenital Anomalies Registry; OMNI‐Net, Ukraine Birth Defects Prevention Program; P, population‐based programme; RENAC, 
National Network of Congenital Anomalies of Argentina; RYVEMCE, Mexican Registry and Epidemiological Surveillance of External Congenital 
Malformations; SMC, Soroka Medical Center; TROCA, Tabriz Registry of Congenital Anomalies; UK, United Kingdom; USA, United States of America.
aETOPFA not allowed. 
bETOPFA not registered. 
cData on liveborn children with spina bifida from one hospital. 
dExcludes programmes where ETOPFA is unavailable, or does not report on ETOPFA. 
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allowed in the surveillance region for 5 of the 24 programmes. In all 
regions covered by the ICBDSR programmes included in our analysis, 
prenatal screening services were offered in recent years (Table 1).
Mortality analysis was mostly restricted to a short postnatal fol‐
low‐up (Table 2). Postnatal follow‐up was performed from birth until 
discharge from the birth hospital in 20 out of the 24 participating 
programmes. The four programmes that did not collect information 
on vital status at hospital discharge or during the delivery hospital‐
isation (Czech Republic, Italy‐Lombardy, Italy‐Tuscany, and Sweden) 
used linkage to vital records to collect information on vital status. In 
total, there were 11 programmes that used linkages to death certifi‐
cates or other health care databases to determine vital status (Czech 
Republic, Italy‐Lombardy, Italy‐Tuscany, Malta‐MCAR, Sweden, 
UK‐Wales, USA‐Arkansas, USA‐Atlanta, USA‐Texas, USA‐Utah, and 
Israel‐Soroka Medical Center). Three programmes collected only 
information on vital status at hospital discharge and did not use 
other follow‐up methods (Slovak Republic, Mexico‐Nuevo Leon, and 
Mexico‐RYVEMCE). Maximum follow‐up period noting infant sur‐
vival varied by programme, but all programmes provided information 
on mortality that occurred in the first week of life.
TA B L E  4   Mortality in spina bifida‐affected births for surveillance period 2001‐2012 from registries contributing to the International 














  N % % % % % %
Argentina‐RENACa 2009‐2012 228 9.6d – – – –
Colombia‐Bogotáb 2001‐2012 104 4.8 – – – – –
South America‐ECLAMCa 2001‐2012 1700 6.5 2.5 1.6 0.8 – –
Czech Republic 2001‐2012 139 0.7 2.9 3.6 1.4 1.4 1.4
France‐Parisb 2001‐2012 34 2.9 2.9 2.9  – –
Germany‐Saxony Anhalt 2001‐2012 41 0 0 0 0 0 –
Italy‐Lombardy 2003‐2012 25 0 0 0 0 4.0 –
Italy‐Tuscany 2001‐2012 22 4.5 0 0 0 – –
Maltaa 2001‐2012 28 0.0 3.6 3.6 0 0 –
Netherlands‐Northern 2001‐2012 55 7.3 18.2 12.7 0 0 0
Slovak Republic 2001‐2012 179 0 5.0 – – – –
Spain‐ECEMC 2001‐2012 23 8.7 0 – – – 0
Sweden 2001‐2012 263 1.5 2.7 1.9 1.5 0.4 0.4
Ukraine‐OMNI‐Net 2001‐2012 169 3.0 2.4 1.8 14.8 1.8 –
UK‐Wales 2001‐2012 78 6.4 1.3 1.3 0 1.3 0
Mexico‐Nuevo Leóna 2011‐2012 23 0 0 – – – –
Mexico‐RYVEMCEa 2001‐2012 160 3.1 1.3 – – – –
USA‐Arkansas 2001‐2012 177 6.2 2.3 1.1 3.4 2.8 1.1
USA‐Atlanta 2001‐2008 112 0.9 0.9 1.8 0.9 0 0
USA‐Texas 2001‐2012 1578 3.5 1.7 1.0 2.2 1.1 0.4
USA‐Utah 2001‐2012 213 6.1 1.4 0.9 0.9 0 0.5
Iran‐TROCA 2004‐2012 22 0.0 4.5 – – – –
Israel‐Soroka Medical Centerc 2001‐2012 47 6.4 14.9 14.9 4.3 2.1 –
Total  5420 4.2 2.7 1.7e 1.9e 1.1e 0.4e
Abbreviations: ECEMC, Registry of the Spanish Collaborative Study of Congenital Malformations; ECLAMC, Latin American Collaborative Study 
of Congenital Malformations; LB, livebirth; MCAR, Malta Congenital Anomalies Registry; OMNI‐Net, Ukraine Birth Defects Prevention Program; 
RENAC, National Network of Congenital Anomalies of Argentina; RYVEMCE, Mexican Registry and Epidemiological Surveillance of External 
Congenital Malformations; SB, Stillbirth; SMC, Soroka Medical Center; TROCA, Tabriz Registry of Congenital Anomalies; UK, United Kingdom; USA, 
United States of America.
aETOPFA not allowed. 
bETOPFA not registered. 
cData on liveborn children with spina bifida from one hospital. 
dPercentage refers to first‐week mortality. 
eExcludes programmes that have no data on mortality for selected age at death. 
fA hyphen means that the registry did not report follow‐up data for that time period. 
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3.2 | Prevalence and pregnancy outcome
Since most programmes provided data for surveillance years 
2001‐2012 (83% of programmes presented data on 2001, increas‐
ing to more than 95% of programmes in 2012), we elected to focus 
our analysis on this time interval. This allowed comparison of results 
between programmes. In Table 3, we present programme‐specific 
spina bifida prevalence per 10 000 total births and the pregnancy 
outcome. The prevalence of spina bifida during 2001‐2012 was 
4.7 per 10 000 total births (95% CI 4.6, 4.8). The highest preva‐
lence estimates of spina bifida per 10 000 total births were ob‐
served in Ukraine‐OMNI‐Net (10.9), South America‐ECLAMC (9.9), 
and UK‐Wales (7.3), whereas Mexico‐Nuevo León (1.4), Iran (1.6), 
Colombia‐Cali (2.4), and Czech Republic (2.9) showed the low‐
est prevalence. The highest proportion of ETOPFA among spina 
bifida cases were observed in four European registries with over 
70% of pregnancies affected with spina bifida electively terminated 
(Spain‐ECEMC, 84.6%; France‐Paris, 81.0%; Italy‐Tuscany, 76.5%; 
and UK‐Wales, 72.7%). Overall, the proportion of stillbirths ranged 
between 0% and 10%, and the proportion of stillbirths was high‐
est in programmes from countries that do not allow termination of 
pregnancy.
The overall results on prevalence of spina bifida, examined as 
a secondary objective of the study, for the complete surveillance 
TA B L E  5   Type of birth and first‐week mortality among livebirths affected with spina bifida according to clinical presentation from 
registries contributing to the International Clearinghouse for Birth Defects Surveillance and Research, 2001‐2012
Country‐registry
Isolated spina bifida Multiple/syndromic spina bifida
Total cases
Type of Birth Mortality in LB
Total cases
Type of Birth Mortality in LB
ETOPFA SB LB Day 1 Day 2‐6 ETOPFA SB LB Day 1
Day 
2‐6
N % % % % % % N % % % % % %
Argentina‐RENACa 189 78 – 2 98 3 52 22 – 17 83 0 40
Colombia‐Bogotáb 96 85 – 5 94 2 0 17 15 – 24 76 15 0
SA‐ECLAMCa 935 51 – 3 97 2 1 884 49 – 10 90 12 4
France‐Paris 139 76 81 1 18 0 4 45 24 80 0 20 11 0
Germany‐Saxony 
Anhalt
103 85 65 1 34 0 0 18 15 61 6 33 0 0
Italy‐Lombardy 34 51 59 0 41 0 0 33 49 64 3 33 0 0
Italy‐Tuscany 73 68 77 0 23 0 0 35 32 77 9 14 20 0
Malta‐MCARa 22 71 – 0 100 0 5 9 29 – 33 67 0 0
Netherlands‐
Northern
80 75 39 4 58 2 17 26 25 46 19 35 33 22
Slovak Republic 150 67 15 1 84 0 1 74 33 24 4 72 0 15
Spain‐ECEMC 112 72 83 0 17 5 0 44 28 89 2 9 25 0
Sweden 441 76 58 0 42 1 2 142 24 44 1 56 3 5
Ukraine‐OMNI‐Nete 333 88 48 3 44 1 1 45 12 42 4 49 18 14
UK‐Wales 238 82 75 0 25 3 0 54 18 63 4 33 17 6
Mexico‐RYVEMCEa 153 91 – 3 97 2 1 16 9 – 31 69 9 0
USA‐Utah 174 70 11 2 87 2 1 75 30 8 11 81 16 2
Israel‐SMCc 45 96 – – 100 2 16 2 4 – – 100 100 0
Total 3317 68 54d 2 67 1 2 1571 32 48d 9 73 11 6
Note: Frequencies for mortality statistics are not presented due to sparse data.
Abbreviations: ECEMC, Registry of the Spanish Collaborative Study of Congenital Malformations; ECLAMC, Latin American Collaborative Study 
of Congenital Malformations; ETOPFA, Elective Termination of Pregnancy for Fetal Anomalies; LB, livebirth; MCAR, Malta Congenital Anomalies 
Registry; OMNI‐Net, Ukraine Birth Defects Prevention Program; RENAC, National Network of Congenital Anomalies of Argentina; RYVEMCE, 
Mexican Registry and Epidemiological Surveillance of External Congenital Malformations; SB, Stillbirth; SMC, Soroka Medical Center; TROCA, Tabriz 
Registry of Congenital Anomalies; UK, United Kingdom; USA, United States of America.
aETOPFA not allowed. 
bETOPFA not registered. 
cData on liveborn children with spina bifida from one hospital. 
dExcludes programmes where ETOPFA is unavailable, or does not report on ETOPFA. 
eType of birth unknown for 16 isolated cases (5%) and 1 multiple/syndromic case. 
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period (1974‐2015), are presented in Table S1. The total number of 
births covered by all programmes was 28 213 327 (including live‐
births and stillbirths), and the total number of spina bifida cases 
equalled to 14 159. Thus, the prevalence of spina bifida in our study 
was estimated to be 5.0 per 10 000 total births (95% CI 4.9, 5.1).
3.3 | Mortality
The overall first‐week mortality (years 2001‐2012) proportion was 
6.9% (95% CI 6.3%, 7.7%) (Table 4). The first‐week mortality pro‐
portion was lower in programmes where ETOPFA was available. 
When taking isolated and complex cases together, the majority of 
deaths occurring during the first week of life were reported to have 
been during the first day of life. However, in Malta (based on 1 case), 
Northern Netherlands, and Israel, the majority of spina bifida deaths 
occurred after the first day. Most (~80%) deaths occurred within the 
first 28 days of life (neonatal period).
A total of 17 programmes provided data on additional birth 
defects co‐occurring with spina bifida. Since the number of spina 
bifida cases with a syndromic aetiology was very small, we pooled 
them with the MCA cases in the analyses. On average, 68% pre‐
sented as isolated and 32% as MCA or as part of a genetic syn‐
drome (Table 5). The distribution varied by programme; in Israel 
and Mexico‐RYVEMCE, more than 90% of spina bifida cases were 
described as isolated, whereas in Italy‐Lombardy and in South 
America‐ECLAMC, 53% and 51% were described as isolated, respec‐
tively. In Europe, where ETOPFA is allowed and common, ETOPFA 
proportion was similar between isolated and MCA/syndromic cases. 
Among all programmes, the proportion of first‐day and first‐week 
mortality was higher in MCA/syndromic cases compared with iso‐
lated cases (Table 5).
Only 10 programmes, from Europe and North America, pro‐
vided information on long‐term mortality (over age 1 year) using 
linkage to vital records. These programmes were Czech Republic, 
Italy‐Lombardy, Malta‐MCAR, Sweden, Italy‐Tuscany, UK‐Wales, 
USA‐Arkansas, USA‐Atlanta, USA‐Texas, and USA‐Utah. In Europe, 
survival up to age 1‐4 years was 90%‐96%, and in North American 
programmes, the survival was similar, at 86%‐96% (Figure 2).
Trends in ETOPFA, stillbirths, and first‐week mortality in live‐
births affected with spina bifida from registries contributing to the 
ICBDSR are presented in Figure S1. Looking at pooled 5‐year, pro‐
gramme‐specific trends in mortality, we found that in most European 
programmes an increase in ETOPFA proportion was observed over 
time, which was accompanied by a decrease in stillbirths and first‐
week mortality (eg Czech Republic, France‐Paris, Germany‐Saxony 
Anhalt, Italy, Northern Netherlands, Spain, and Sweden). In the 
Slovak Republic, the proportion of ETOPFA, stillbirth, and first‐week 
mortality declined in the most recent study period (2011‐2014). In 
UK‐Wales, a decline in ETOPFA was also observed but with stable 
stillbirth and first‐week mortality proportions. In the United States, 
a decreasing trend in the ETOPFA proportion was observed during 
the same period, with a relatively stable or decreasing stillbirth and 
first‐week mortality proportions (except for USA‐Texas, where an 
increase in first‐week mortality was observed). In Mexico‐RYVMCE, 




This is the first multi‐country, multi‐registry study that provides 
estimates of prevalence, perinatal and infant and child mortality, 
and mortality trends among those born with spina bifida using 
data from 24 birth defects programmes in 18 countries affiliated 
with the ICBDSR. Our findings confirm that a substantial propor‐
tion of pregnancies affected by spina bifida end in ETOPFA, still‐
births, or infant mortality in the countries examined. The highest 
ETOPFA proportion was observed in some European registries, 
with over 70% of pregnancies affected with spina bifida electively 
terminated. Overall, up to 10% of infants born with spina bifida 
died either on the first day or by the first month of life. We ob‐
served a higher occurrence of stillbirths and neonatal mortality 
in countries in which termination of pregnancy after fetal diagno‐
sis for congenital malformations was not available. We also found 
that the proportion of perinatal deaths were higher among cases 
with other anomalies or genetic syndromes compared with iso‐
lated cases. Our study allowed a comparison of findings between 
participating programmes.
4.2 | Strengths of the study
Our study was the first to examine perinatal and infant child mortal‐
ity among those born with spina bifida in a diverse set of populations 
using multi‐registry, multi‐country data. International Clearinghouse 
for Birth Defects Surveillance and Research programmes have qual‐
ity control protocols to enhance case specificity for spina bifida, 
while tracking cases from multiple data sources. We were able 
to examine all birth outcomes, including stillbirths and ETOPFA. 
Information on whether infants with spina bifida had additional birth 
defects was available for most programmes. Mortality outcomes 
were examined by age. Most programmes had information on mor‐
tality during the first week of life, and we could compare findings 
between programmes. Programmes provided information on exist‐
ing policies on ETOPFA, which allowed us to compare findings by 
ETOPFA policies. Mortality outcomes were pooled by isolated and 
non‐isolated cases of spina bifida.
4.3 | Limitations of the data
There were several limitations in our study. First, programmes that 
contributed data were not homogenous in methods; and the surveil‐
lance periods varied. We did not have individual‐level data. We may 
have missed some cases as programmes may not have captured all 
stillbirths and ETOPFA cases. Accuracy of mortality outcomes, and age 
at death, cannot be confirmed. Data linkages with death certificates 
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were not uniform across all programmes. We were unable to examine 
temporal trends in mortality for programmes that provided data for 
short durations (ie <5 years). There may have been deaths that could 
not be tracked due to limitations in administrative data linkages, or if 
they occurred outside the programme surveillance area.
4.4 | Interpretation
The average prevalence of spina bifida (including all cases) in our 
analysis, using data from 24 programmes reporting to ICBDSR, 
was 5.0 per 10 000 total births. This prevalence is very similar to 
the total prevalence reported by programmes that are full members 
of the EUROCAT (European Surveillance of Congenital Anomalies) 
network, which includes most population‐based congenital anomaly 
registries in Europe with a common database (www.euroc at‐netwo 
rk.eu/), at 5.1 per 10 000 total births, between years 1980 and 2015. 
Some of the surveillance programmes participate in both ICBDSR and 
EUROCAT (full members) (France‐Paris, Germany‐Saxony Anhalt, 
Italy‐Tuscany, Malta‐MCAR, Northern Netherlands, Ukraine‐OMNI‐
Net, and UK‐Wales). Our analysis included countries outside the 
EUROCAT network, including Argentina, Colombia, South America‐
ECLAMC, Czech Republic, Mexico, USA, Iran, and Israel, contributing 
additional data to the existing literature from EUROCAT countries.
We noted that the first‐week mortality among spina bifida cases 
was highest in Northern Netherlands (25.5%) and Israel (21.3%). In 
the Northern Netherlands, a prenatal screening programme was in‐
troduced in 2007, after which the first‐week mortality dropped from 
31.4% to 15.0% (data not shown). The data from Israel are from one 
hospital and therefore may not be representative of the country.
Survival among spina bifida cases is known to be influenced neg‐
atively by low birthweight and high lesions, and positively by surgical 
interventions soon after birth.20,22,23 In our study, we also observed 
that mortality in cases with isolated spina bifida is lower than in cases 
with spina bifida and other anomalies or syndromes. A probable ex‐
planation is that isolated cases are less complicated. Overall, the gen‐
eral consensus is that the survival probability in developed countries 
is about 80% up to age 1 year,16,24 and the higher probability of death 
persists with increasing age among those with spina bifida compared 
to those without.16,17,25 Wang et al (2010) reported that the relative 
risk of death among children born with spina bifida is 10 times (95% 
CI 7.5, 13.5) greater compared with children born without birth de‐
fects at age 6 or older.26 Sex, age, race and ethnicity, severity of the 
lesion, multiple birth defects, birth year, and availability, use, and ac‐
ceptance of medical and surgical treatments have been associated 
with variations in mortality in spina bifida worldwide.1,16‐18
Population‐based state registry data with linkage to death cer‐
tificates in New York, USA, identified hydrocephalus, infections, 
cardiac anomalies, pneumonia, and pulmonary embolism as common 
causes of death in children with spina bifida.18 We were unable to 
examine specific causes of death and the influence of birthweight, 
F I G U R E  2   Survival in livebirths with spina bifida for surveillance period 2001‐2012, from European and North American registries (with 
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lesion severity, and other aforementioned factors on mortality as‐
sociated with spina bifida, as data were unavailable and beyond the 
scope of our current analysis.
We noted an increasing trend in ETOPFA for spina bifida in 
European programmes, with a concomitant decrease in stillbirths 
and first‐week mortality proportions. A retrospective cohort study 
from the Netherlands examining the impact of introduction of the 
mid‐trimester scan during the year 2007 on pregnancy outcome of 
spina bifida cases diagnosed pre‐ or postnatally reported that preg‐
nancies that previously might have ended in a perinatal loss are now 
terminated, while pregnancies with a relatively good prognosis are 
frequently not terminated; the overall number of liveborn children 
with spina bifida has not changed significantly.27
5  | CONCLUSIONS
Data from 24 programmes provided a first summary of spina bi‐
fida‐associated perinatal and infant and child mortality and their 
trends. In the many countries that contributed data for our analy‐
sis, mortality among those affected with spina bifida is a major 
concern, especially during the first day and first week of life. 
Additional data, including sociodemographic and clinical factors, 
could be utilised to further understand disparities in mortality that 
we observed in different programmes. Mortality in spina bifida is 
preventable through timely surgical and medical care at birth and 
beyond, and advanced health care throughout the life course of 
those affected. Findings from our analysis can inform policymak‐
ers of the need for primary prevention of spina bifida with folic 
acid interventions to address preventable mortality associated 
with this severe and often fatal birth defect. Primary prevention 
of spina bifida through folic acid fortification and supplementa‐
tion should be considered the first policy in any country to avoid 
unnecessary disability and mortality associated with spina bifida.
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